A Randomized Controlled Trial for the Efficacy of Liver Resection and TACE Combined with Radiotherapy in Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombus

A Multicenter Prospective Randomized Controlled Trial for the Efficacy of Liver Resection and TACE Combined with Radiotherapy in Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000035704

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-10-16

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma, combined portal vein tumor thrombosis

Interventions

Liver resection (LR):Liver resection (LR)

TACE+RT:TACE+RT

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18-70 years old; 2. Clinical diagnosis of hepatocellular carcinoma (clinical diagnostic criteria for hepatocellular carcinoma: in line with the diagnostic criteria for the diagnosis and treatment of primary liver cancer in 2019); 3. There is a clear tumor thrombus in imaging studies, and the tumor thrombus has not reached the main portal vein, (Cheng's classification I and II, Japan Vp1-Vp3); 4. No clear distant transfer; 5. Have not received other anti-tumor treatments in the past; 6. Tumors and tumor thrombi can be completely removed (3 liver surgery experts judged that the tumor and tumor thrombi can be removed before treatment, and the remaining liver volume after tumor and tumor thrombi resection is sufficient, and the tumor thrombus does not invade the main portal vein.) 7. Good general condition (ECOG 0-2); 8. Good liver function (Child-Pugh score A); 9. Know the research process and agree to participate, sign relevant informed consent and other documents

Exclusion criteria

Exclusion criteria: 1. Have a history of other tumors; 2. Severe accompanying diseases; 3. With portal hypertension (esophageal and gastric varices, PLT<100, severe gastroscopic esophagus and gastric varices or previous history of upper gastrointestinal bleeding) 4. Uncontrollable ascites or hepatic encephalopathy; 5. Combined with HIV infection; 6. Women during pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
Overall Survival;	—

Countries

China

Contacts

Public ContactZhou Weiping

Third Affiliated Hospital of the Second Military Medical University

ehphwp@126.com+86 13601616763

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026